Group 1 - The company, Kangzheng Pharmaceutical, has signed a distribution agreement with Novartis Pharma Services AG for the exclusive import, distribution, sales, and promotion rights of two injectable products in mainland China [1][2] - The agreement covers the products Lezhu Single Antibody Injection (brand name: Noshide) and Busizhu Single Antibody Injection (brand name: Beiyoushi), with Novartis responsible for production and supply [1] - The collaboration is set to last for five years from the effective date of the agreement [1] Group 2 - This partnership is expected to enhance the competitiveness of Kangzheng Weisheng in the ophthalmology sector, which already covers diseases such as retinal diseases, visual fatigue, and glaucoma [2] - The addition of Noshide and Beiyoushi will synergize with existing products, including the exclusive eye drop medication and glaucoma treatment device, improving academic brand competitiveness in the ophthalmology field [2] - The professional ophthalmology team at Kangzheng Weisheng will integrate market channels and academic resources, leading to improved overall team efficiency and a positive impact on the company's performance [2]
康哲药业(00867)与诺华签订眼科药物诺适得®与倍优适®经销协议